Skip to main content

Appili Therapeutics Inc(APLI-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0200
Day High0.0200
Open:0.0200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Appili Therapeutics Inc

Select a category then submit the form to load news
Stocks in play: Appili Therapeutics Inc.
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Stocks in play: Appili Therapeutics Inc.
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Stocks in play: Appili Therapeutics Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Stocks in play: Appili Therapeutics Inc.
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Stocks in play: Appili Therapeutics Inc.
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Appili Therapeutics Announces Results of Special Meeting of Shareholders

Profile

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.